CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Westwood, Kansas, United States and 59 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
Kansas City, Kansas, United States and 126 other locations
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...
Phase 2
Westwood, Kansas, United States and 46 other locations
(LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line treatment of ...
Phase 2
Kansas City, Missouri, United States and 48 other locations
determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple...
Phase 2
Kansas City, Kansas, United States and 40 other locations
phase 3 dose (RP3D) in adult participants with newly diagnosed multiple myeloma (NDMM). Participants will receive the combination o...
Phase 1
Westwood, Kansas, United States and 40 other locations
monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Pa...
Phase 3
Mission, Kansas, United States and 239 other locations
(Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma...
Phase 3
Kansas City, Kansas, United States and 143 other locations
combination with DEX for Relapsed Refractory Multiple Myeloma (RRMM), CC-220 in combination with DEX and BTZ, and CC-220 in combin ...
Phase 1, Phase 2
Fairway, Kansas, United States and 88 other locations
antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is either at ...
Phase 1
Westwood, Kansas, United States and 25 other locations
Clinical trials
Research sites
Resources
Legal